Title:
USE OF CD166 AS A SERUM MARKER FOR DIAGNOSIS OF LIVER CANCER AND KIT THEREFOR
Document Type and Number:
WIPO Patent Application WO/2016/065877
Kind Code:
A1
Abstract:
The present invention relates to a use of CD166 as a serum marker for the diagnosis of liver cancer and a kit therefor, which can diagnose and indicate liver cancer disease by detecting the concentration of CD166 in the blood serum.
Inventors:
SUN FENYONG (CN)
WANG JIAYI (CN)
WANG JIAYI (CN)
Application Number:
PCT/CN2015/077658
Publication Date:
May 06, 2016
Filing Date:
April 28, 2015
Export Citation:
Assignee:
SHANGHAI 10TH PEOPLES HOSPITAL (CN)
International Classes:
G01N33/574; G01N33/68
Other References:
MA, LIFANG ET AL.: "Serum CD 166: ANovel Hepatocellular Carcinoma Tumor Marker", CLINICA CHIMICAACTA, vol. 441, 4 January 2015 (2015-01-04), pages 156 - 162, XP029196049
HANA, V. ET AL.: "Comparative Study of SPR and ELISA Methods Based on Analysis of CD 166/ALCAM Levels in Cancer and Control Human Sera", BIOSENSORS AND BIOELECTRONICS, vol. 24, 27 November 2008 (2008-11-27), pages 2143 - 2148, XP025958991
YU , WENJUN ET AL.: "CD 166 Plays a Pro-carcinogenic Role in Liver Cancer Cells via Inhibition of FOXO Proteins through AKT", ONCOLOGY REPORTS, vol. 32, no. 2, 31 August 2014 (2014-08-31), pages 677 - 683, XP055278290
HANA, V. ET AL.: "Comparative Study of SPR and ELISA Methods Based on Analysis of CD 166/ALCAM Levels in Cancer and Control Human Sera", BIOSENSORS AND BIOELECTRONICS, vol. 24, 27 November 2008 (2008-11-27), pages 2143 - 2148, XP025958991
YU , WENJUN ET AL.: "CD 166 Plays a Pro-carcinogenic Role in Liver Cancer Cells via Inhibition of FOXO Proteins through AKT", ONCOLOGY REPORTS, vol. 32, no. 2, 31 August 2014 (2014-08-31), pages 677 - 683, XP055278290
Attorney, Agent or Firm:
SHANGHAI ZHUOYANG INTELLECTUAL PROPERTY AGENT FIRM (CN)
上海卓阳知识产权代理事务所（普通合伙） (CN)
上海卓阳知识产权代理事务所（普通合伙） (CN)
Download PDF: